Company
Headquarters: Beijing, China
Employees: 2,576
CEO: Mr. Enlin Jin
€11.89 Billion
EUR as of Jan. 1, 2025
US$12.37 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health and wellness products through direct selling and online retail pharmacy network. The company also provides online healthcare services, such as online consultation, prescription renewal, chronic disease management, family doctor, and consumer healthcare services; health management and intelligent healthcare solutions, as well as technical and advertising services. In addition, its platform allows users to book appointments and pay for services, such as general physical exams, aesthetic medicines, vaccination appointments, dental care services, and nucleic acid testing tests. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | €7.23 B |
| EBITDA | €3.00 B |
| Gross Profit TTM | €1.63 B |
| Profit Margin | 4.78% |
| Operating Margin | 3.65% |
| Quarterly Revenue Growth | 4.60% |
JD Health International, Inc. has the following listings and related stock indices.
Stock: FSX: 8ZN wb_incandescent
Stock: OTC: JDHIF wb_incandescent